$GROY

FY2026 EPS Estimates for Gold Royalty Lowered by Scotiabank

Scotiabank has lowered its FY2026 earnings per share estimate for Gold Royalty Corp. (NYSEAMERICAN:GROY) from $0.11 to $0.09, while maintaining an "Outperform" rating and a $6.00 price target. The company currently holds an average analyst rating of "Moderate Buy" with a consensus price target of $5.64, and its shares recently traded around $3.68. Institutional investors, including Goldman Sachs and JPMorgan Chase, have significantly increased their stakes in the company, with approximately 33.75% of the stock owned by hedge funds and other institutional investors.

Original reporting
MarketBeat · MarketBeat
Published Apr 3, 2026, 11:26 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Apr 3, 2026, 12:00 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
FY2026 EPS Estimates for Gold Royalty Lowered by Scotiabank — source image
Decision brief

The 30-second read

$GROYBearishMed
01

Why it matters

The downgrade reflects concerns about future earnings, possibly due to gold price assumptions or project developments, influencing investor sentiment.

02

Market read

The news has moderate relevance for gold royalty stocks, especially GROY, due to earnings revision and institutional activity.

03

What to watch

Potential for GROY to benefit from rising gold prices or new project developments, which could offset earnings pressure.

Relevance 6/10Timing: short to medium term (next 1-3 months)

Background

Gold Royalty Corp. is a gold-focused royalty and streaming company with exposure to various mining projects. Earnings estimates are a key indicator of future profitability.

Company-level read

Ticker impact

$GROYBearishMedium confidence
Context

The news pertains directly to Gold Royalty Corp., impacting its valuation and investor sentiment.

Expected impact

Potential short-term decline in GROY stock price due to earnings estimate reduction, with possible stabilization as institutional confidence remains.

Evidence & confidence

The EPS downgrade signals potential earnings pressure; however, strong institutional ownership and maintained rating suggest limited downside risk and possible recovery.

$GROYBearishMedium confidence
Context

The news directly affects GROY's valuation and investor sentiment, making it highly relevant for trading decisions.

Expected impact

Possible 5-10% decline in stock price in the near term, with longer-term prospects remaining uncertain.

Evidence & confidence

Earnings revisions often influence stock prices; institutional buying may mitigate declines over time.

Market effects

Potential negative sentiment affecting the precious metals royalty sector; investors may reassess valuations.

Limited regional impact, primarily affecting North American markets where GROY is listed.

Low; the news is company-specific with minimal direct global market influence.

Counterpoint

The EPS downgrade may be already priced in, and institutional buying suggests confidence in GROY's long-term prospects.

Key entities

  • Gold Royalty Corp.

    A gold-focused royalty and streaming company.

  • Scotiabank

    The bank that lowered GROY's FY2026 EPS estimates.

  • Gold Royalty's institutional investors

    Includes Goldman Sachs, JPMorgan Chase, and hedge funds.

Related articles

$GROYMed

Gold Royalty Q2 Earnings Call Highlights

Gold Royalty Corp (GROY) discussed its Q2 earnings call, saying its NSR royalty model is based on revenue and can be insulated from mine operating cost inflation. It maintained 2026 guidance of 7,500 to 9,300 GEOs, with 1H at 44% of the midpoint. It also outlined ramp-up and acquisition updates, including a $6.25M REN NSR add-on and new Nevada royalties.

$GROYHigh

Gold Royalty Corp. (GROY): Financial results for H1 2026

Gold Royalty Corp. (GROY) furnished an SEC Form 6-K — earnings release. Exhibit 99.1 Gold Royalty Reports record SIX-MONTH results with continued strong cash flow and EARNINGS growth Vancouver, British Columbia – August 5, 2026 – Gold Royalty Corp. (“ Gold Royalty ” or the “ Company ”) (NYSE American: GROY) is pleased to announce the filing of its op

$GMABMedAI 9/10

Genmab A/S: Genmab Announces Rinatabart Sesutecan (Rina-S) Phase 2 RAINFOL-01 Results Demonstrated Durable and Clinically Meaningful Responses in Patients with Platinum-Resistant Ovarian Cancer

Genmab A/S (Nasdaq: GMAB) announced Phase 2 trial results for rinatabart sesutecan (Rina-S) in platinum-resistant ovarian cancer. The treatment showed a 45.9% objective response rate and a median duration of response of 12.1 months. The study included 109 patients and was presented at the IGCS Congress 2026. Rina-S is being evaluated in multiple Phase 3 trials for various gynecologic cancers.

$GMABMedAI 8/10

Genmab reports trial results for ovarian cancer drug candidate

Genmab (GMAB) reported Phase 1/2 trial results for rinatabart sesutecan in platinum-resistant ovarian cancer, showing a 45.9% response rate and median progression-free survival of 9.5 months. The trial involved 109 patients, with common side effects including fatigue, nausea, and anemia. The drug is being evaluated in four Phase 3 trials for various gynecologic cancers.